Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trientine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.92 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.92 |
| ▸ | CA6 | P23280 | 5/20 | 0.92 |
| ▸ | CA7 | P43166 | 5/20 | 0.92 |
| ▸ | CA9 | Q16790 | 5/20 | 0.92 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.92 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.92 |
| ▸ | CA4 | P22748 | 4/20 | 0.92 |
| ▸ | CA5A | P35218 | 4/20 | 0.92 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.92 |
| ▸ | CA3 | P07451 | 3/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.92 |
| ▸ | CA1 | P00915 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.92 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28797750 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL285388 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL506113 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL284758 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL2027642 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL505712 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL506189 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL1625351 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL1626082 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL28797761 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 848 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688828-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | Jubilant DraxImage Inc. (CA) | 2026-02-11 | — | — | EP | claimed |
| US-12539339-B2 | Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof | JUBILANT DRAXIMAGE INC. (IN) | 2026-02-03 | — | — | US | claimed |
| WO-2025099636-A1 | ALBUMIN CONJUGATES AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF | JUBILANT DRAXIMAGE INC (CA) | 2025-05-15 | — | — | WO | claimed |
| US-20250144254-A1 | ALBUMIN CONJUGATES AND RADIOPHARMACEUTICAL COMPOSITION THEREOF | JUBILANT DRAXIMAGE INC. (CA) | 2025-05-08 | — | — | US | claimed |
| WO-2024201255-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | JUBILANT DRAXIMAGE INC. (CA) | 2024-10-03 | — | — | WO | claimed |
| US-20240316226-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF | JUBILANT DRAXIMAGE INC. (CA) | 2024-09-26 | — | — | US | claimed |
| CN-118562473-A | Double-layer coated microcapsule corrosion inhibitor for oil and gas field and preparation method thereof | 中国石油天然气股份有限公司 | 2024-08-30 | — | — | CN | claimed |
| EP-4210751-A1 | ANTI-CERULOPLASMIN ANTIBODIES AND USES THEREOF | Alexion Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | claimed |
| US-20220334135-A1 | METHODS OF MEASURING COPPER CONCENTRATION IN BIOLOGICAL SAMPLES | ALEXION PHARMACEUTICALS, INC. (US) | 2022-10-20 | — | — | US | claimed |
| CN-110448994-B | Process method for trapping NO by using renewable amino functional eutectic solvent | 北京化工大学 | 2022-08-05 | — | — | CN | claimed |
| EP-1069821-A4 | METHOD OF CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM AND PROGENITOR CELLS | GAMIDA CELL LTD (IL) | 2001-11-21 | — | — | EP | claimed |
| EP-1119345-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2001-08-01 | — | — | EP | claimed |
| EP-1117762-A1 | METHODS OF CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM AND PROGENITOR CELLS | Gamida Cell Ltd. (IL) | 2001-07-25 | — | — | EP | claimed |
| EP-1069821-A1 | METHOD OF CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM AND PROGENITOR CELLS | Gamida Cell Ltd. (IL) | 2001-01-24 | — | — | EP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2000018885-A1 | METHODS OF CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM AND PROGENITOR CELLS | GAMIDA CELL LTD. (IL) | 2000-04-06 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999040783-A1 | METHOD OF CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM AND PROGENITOR CELLS | GAMIDA CELL LTD. (IL) | 1999-08-19 | — | — | WO | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539339-B2 | Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof | SLC7A1, SLC39A11, SLC39A3 | CA2 253/4885ESR1 3148/4885KDM4E 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.